U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C41H63NO14.C4H4O4
Molecular Weight 910.0094
Optical Activity UNSPECIFIED
Defined Stereocenters 19 / 19
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of PROTOVERATRINE A MALEATE

SMILES

OC(=O)\C=C/C(O)=O.CC[C@@H](C)C(=O)O[C@H]1[C@H](O)[C@H]2[C@@H](CN3C[C@@H](C)CC[C@H]3[C@@]2(C)O)[C@@H]4C[C@@]56O[C@@]7(O)[C@@H]([C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H]5[C@]14O)[C@]6(C)CC[C@@H]7OC(=O)[C@@](C)(O)CC

InChI

InChIKey=XEYDAFGYRVFUOG-PYKTZGOISA-N
InChI=1S/C41H63NO14.C4H4O4/c1-10-20(4)34(46)55-33-28(45)27-23(18-42-17-19(3)12-13-25(42)38(27,9)49)24-16-39-32(40(24,33)50)30(53-22(6)44)29(52-21(5)43)31-36(39,7)15-14-26(41(31,51)56-39)54-35(47)37(8,48)11-2;5-3(6)1-2-4(7)8/h19-20,23-33,45,48-51H,10-18H2,1-9H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t19-,20+,23-,24-,25-,26-,27+,28+,29-,30+,31-,32+,33-,36-,37-,38+,39+,40-,41?;/m0./s1

HIDE SMILES / InChI

Molecular Formula C41H63NO14
Molecular Weight 793.9372
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 19 / 19
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description

Protoveratrine A, the principal alkaloid of Veratrum album, has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PubMed

PubMed

TitleDatePubMed
The use of protoveratrine in the treatment of hypertensive vascular disease.
1953 Oct
Protoveratrine A in treatment of hypertension.
1957 Sep 14
Patents

Sample Use Guides

In Vivo Use Guide
Out-patient Treatment of hypertension with Protoveratrine A: The duration of treatment has been from one month to as long as two years (mean nine months). The total treatment months were 155. The dosage employed varied from 0.5 to 3.6 mg daily. The drug was taken three times daily after meals and an additional dose often on retiring.
Route of Administration: Oral
In Vitro Use Guide
Protoveratrine A increased the release of gamma-amino[3H]butyrate from small slices of rat cerebral cortex. This effect increased with increasing protoveratrine concentration, reaching a maximum at 100 uM. 2. Removal of Ca2+ from the superfusing medium did not change the increase in release due to 10 uM-protoveratrine.
Substance Class Chemical
Created
by admin
on Tue Oct 22 16:32:25 UTC 2019
Edited
by admin
on Tue Oct 22 16:32:25 UTC 2019
Record UNII
I207Y1N7M6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PROTOVERATRINE A MALEATE
Common Name English
CEVANE-3,4,6,7,14,15,16,20-OCTOL, 4,9-EPOXY-, 6,7-DIACETATE 3-(2-HYDROXY-2-METHYLBUTANOATE) 15-(2-METHYLBUTANOATE), (3.BETA.(S),4.ALPHA.,6.ALPHA.,7.ALPHA.,15.ALPHA.(R),16.BETA.)-, (2Z)-2-BUTENEDIOATE (SALT)
Common Name English
Code System Code Type Description
PUBCHEM
91667955
Created by admin on Tue Oct 22 16:32:26 UTC 2019 , Edited by admin on Tue Oct 22 16:32:26 UTC 2019
PRIMARY
CAS
20397-93-7
Created by admin on Tue Oct 22 16:32:26 UTC 2019 , Edited by admin on Tue Oct 22 16:32:26 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY